Psychological factors as a predictor of treatment response in patients with heartburn: A pooled analysis of clinical trials

Scandinavian Journal of Gastroenterology

Volumn 41, Issue 3, 2006, Pages 288-293

  Wiklund, Ingela ^a   Carlsson, Rolf ^a   Carlsson, Jonas ^a   Glise, Hans ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

Acid suppression; Anxiety; Gastroesophageal reflux disease; Health related quality of life; Heartburn; Proton pump inhibitor; Symptoms; Treatment; Well being

Indexed keywords

OMEPRAZOLE; RANITIDINE;

ADOLESCENT; ADULT; AGED; ANXIETY; ANXIETY DISORDER; ARTICLE; BODY MASS; CHILD; CONTROLLED STUDY; DATA ANALYSIS; DEPRESSION; ENDOSCOPY; FEMALE; GASTROINTESTINAL REFLUX; HEARTBURN; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NEWBORN; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PSYCHOLOGICAL ASPECT; REFLUX ESOPHAGITIS; SCORING SYSTEM; SEX DIFFERENCE; STOMACH ACID; SYMPTOM; TREATMENT OUTCOME; WELLBEING;

EID: 33644596663     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.1080/00365520500292970     Document Type: Article

References (35)

1. Galmiche JP, Janssens J. The pathophysiology of gastrooesophageal reflux disease: an overview. Scand J Gastroenterol 1995;30 Suppl 211:7-18.
2. Dimenas E, Carlsson G, Glise H, Israelsson B, Wiklund I. Relevance of norm values as part of the documentation of quality of life instruments for use in upper gastrointestinal disease. Scand J Gastroenterol 1996;31 Suppl 221:8-13.
3. Revicki DA, Wood M, Maton PN, Sorensen S. The impact of gastroesophageal reflux disease on health-related quality of life. Am J Med 1998;104:252-8.
4. Dimenas E, Glise H, Hallerback B, Hernqvist H, Svedlund J, Wiklund I. Well-being and gastrointestinal symptoms among patients referred to endoscopy owing to suspected duodenal ulcer. Scand J Gastroenterol 1995;30:1046-52.
5. Wahlqvist P, Carlsson J, Wiklund I, Stålhammar N-O. Measuring lost productivity in patients with GORD using a productivity questionnaire (WPAI-GORD). Qual Life Res 1999,8:576.
6. Wiklund I, Bardhan KD, Muller-Lissner S, Bigard MA, Bianchi Porro G, Ponce J, et al. Quality of life during acute and intermittent treatment of gastro-oesophageal reflux disease with omeprazole compared with ranitidine. Ital J Gastroenterol Hepatol 1998;30:19-27.
7. Wiklund I, Glise H. Quality of life in different gastrointestinal conditions. Eur J Surg 1998;164 Suppl 582:56-61.
8. Glise H, Hallerbäck B, Wiklund I. Quality of life a reflection of symptoms and concerns. Scand J Gastroenterol 1996;31 Suppl 221:14-7.
9. Wiklund I. Quality of life in patients with gastroesophageal reflux disease. Am J Gastroenterol 2001;96 Suppl 8:46-53.
10. Dent J. Long-term aims of treatment of reflux disease, and the role of non-drug measures. Digestion 1992;51 Suppl 1:30-4.
11. Dent J, Brun J, Fendrick AM, Fennerty MB, Janssens J, Kahrilas PJ, et al. An evidence-based appraisal of reflux disease management: the Genval Workshop Report. Gut 1999;44 Suppl 2:S1-16.
12. Wiklund I. Aspects of quality of life in gastrointestinal disease: some methodological issues. Scand J Gastroenterol 1995;208:129-32.
13. Chiba N. Proton pump inhibitors in acute healing and maintenance of erosive or worse oesophagitis: a systematic overview. Can J Gastroenterol 1997;II Suppl B:66B-73.
14. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997;112:1798-810.
15. Havelund T, Lind T, Wiklund I, Glise H, Hernqvist H, Lauritsen K, et al. Quality of life in patients with heartburn but without oesophagitis: effects of treatment with omeprazole. Am J Gastroenterol 1999;94:1782-9.
16. Carlsson R, Dent J, Watts R, Riley S, Sheikh R, Hatlebakk J, et al. Gastro-oesophageal reflux disease (GORD) in primary care: an international study of different treatment strategies with omeprazole. Eur J Gastroenterol Hepatol 1998;10:119-24.
17. Venables TL, Newland RD, Patel AC, Hole J, Wilcock C, Turbitt ML. Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice. Scand J Gastroenterol 1997;32:965-73.
18. Revicki DA, Crawley JA, Zodet MW, Levine DS, Joelsson BO. Complete resolution of heartburn symptoms and health-related quality of life in patients with gastroesophageal reflux disease. Aliment Pharmacol Ther 1999;13:1621-30.
19. Lind T, Havelund T, Carlsson R, Anker-Hansen O, Glise H, Hernqvist H, et al. Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 1997;32:974-9.
20. Sandmark S, Carlsson R, Fausa O, Lundell L. Omeprazole or ranitidine in the treatment of reflux oesophagitis. Results from a double-blind randomized multicentre study. Scand J Gastroenterol 1988;23:625-32.
21. Glise H, Hallerback B, Johansson B. Quality of life assessments in the evaluation of gastrointestinal reflux and peptic ulcer disease before, during and after treatment. Scand J Gastroenterol 1995;30:133-5.
22. Glise H, Wiklund I. Measurement of the impact of heartburn and dyspepsia on quality of life. Aliment Pharmacol Ther 1997;11:73-7.
23. Dupuy HJ. The Psychological General Well-Being (PGWB) Index. In: Wenger NK, Mattson ME, Furbery CD, et al., editors. Assessment of quality of life in clinical trials of cardiovascular therapies. New York: Le Jacq Publishing Inc; 1984. pp 170-83.
24. Chal KL, Stacey JH, Sacks GE. The effect of ranitidine on symptom relief and quality of life in patients with gastrooesophageal reflux disease. Br J Clin Pract 1995;49:73-7.
25. Dimenas E, Glise H, Hallerback B, Hernqvist H, Svedlund J, Wiklund I. Quality of life in patients with upper gastrointestinal symptoms: an improved evaluation of treatment regimens? Scand J Gastroenterol 1993;28:681-7.
26. Rush DR, Stelmach WJ, Young TL, Kirchdoerfer LJ, Scott-Lennox J, Holverson HE, et al. Clinical effectiveness and quality of life with ranitidine vs placebo in gastroesophageal reflux disease patients: a clinical experience network (CEN) study. J Fam Pract 1995;41:126-36.
27. Baker LH, Lieberman D, Oehlke M. Psychological distress in patients with gastroesophageal reflux disease. Am J Gastroenterol 1995;90:1797-803.
28. Johnston BT, Lewis SA, Love AH. Psychological factors in gastro-oesophageal reflux disease. Gut 1995a;36:481-2.
29. Bradley LA, Richter JE, Pulliam TJ, Haile JM, Scarinci IC, Schan CA, et al. The relationship between stress and symptoms of gastroesophageal reflux: the influence of psychological factors. Am J Gastroenterol 1993;88:11-9.
30. Wiklund I, Butler-Wheelhouse P. Psychosocial factors and their role in symptomatic gastroesophageal reflux disease and functional dyspepsia. Scand J Gastroenterol 1996;31 Suppl 220:94-100.
31. Johnston BT, Lewis SA, Collins JS, McFarland RJ, Love AH. Acid perception in gastro-oesophageal reflux disease is dependent on psychosocial factors. Scand J Gastroenterol 1995b;30:1-5.
32. Lydeard S, Jones RH. Factors affecting the decision to consult with dyspepsia: comparison of consulters and non-consulters. J R Coll Gen Pract 1989;39:495-8.
33. Crawley JA, Hamelin B, Gallagher E. Does it matter why heartburn sufferers seek healthcare? Gastroenterology 2000;118 Suppl 2:A209 [abstract].
34. Kulig M, Leodolter A, Vieth M, Schulte E, Jaspersen D, Labenz J, et al. Quality of life in relation to symptoms in patients with gastro-oesophageal reflux disease: an analysis based on the ProGERD initiative. Aliment Pharmacol Ther 2003;18:767-76.
35. Axelrod DA, Divi V, Ajluni MM, Eckhauser FE, Colletti LM. Influence of functional bowel disease on outcome of surgical antireflux procedures. J Gastrointest Surg 2002;6:632-7.